Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

UPDATE 1- Weed company Aphria to buy rival Nuuvera for C$826 mln

Published 2018-01-29, 08:26 a/m
© Reuters.  UPDATE 1- Weed company Aphria to buy rival Nuuvera for C$826 mln
APHA
-
ACB
-
CMED
-
NUU
-

Jan 29 (Reuters) - Canadian cannabis company Aphria Inc APH.TO on Monday said it would buy rival Nuuvera Inc NUU.V for C$826 million ($670 million) to expand globally, ahead of Canada's proposed legalisation of recreational weed by mid 2018.

The move comes days after the marijuana industry saw its biggest deal ever, when Aurora Cannabis ACB.TO said it would buy CanniMed CMED.TO for C$1.1 billion. marijuana is already legal in Canada, but the sector is expected to get a boost from exports as many other countries move closer to legalisation.

Aphria will leverage Nuuvera's network in countries like Germany, Italy, Spain, the United Kingdom and Uruguay to create an international footprint, the companies said. It will pay C$8.50 per share to Nuuvera shareholders, a 21.4-percent premium to Nuuvera's Friday close.

Clarus Securities was strategic adviser and Stoic Advisory was financial adviser to Aphria. Stikeman Elliott LLP acted as the company's legal counsel.

Canaccord Genuity was financial adviser and Norton Rose Fulbright Canada acted as legal counsel to Nuuvera.

($1 = 1.2335 Canadian dollars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.